Harvard Apparatus Regenerative Technology, Inc. (HRGN) Form 10-Q — May 13, 2026
Harvard Apparatus Regenerative Technology, Inc. (HART) reported a significant increase in product revenue, growing from $45,000 in Q1 2025 to $226,000 in Q1 2026, a 402% increase. This growth was driven by expanded distribution and new product launches within the Consumer Health segment, including CoQ-10 and sleep aid gummies, alongside continued strong performance from existing offerings such as Liver Guard. Despite the revenue growth, HART continues to incur substantial operating losses.
Key figures
- Eps Beat
- 0
- Revenue
- 226
- Total Debt
- 0
- Debt Amount
- 0
- Revenue Yoy
- 402
- Total Assets
- 1798
- Cash Position
- 419
- Deal Value Usd
- 0
- Interest Rate
- 0
- Gross Proceeds
- 0
- Offering Price
- 0
- Shares Offered
- 0
- Shares Outstanding
- 17580744
- Debt financing
- 500
- Security deposit
- 14
- Long term prepaid contracts
- 752
Price after filing
Close on the filing date to close N calendar days later (from $1.50). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.